These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 28728855)

  • 1. Tissue plasminogen activator (tPA) signal sequence enhances immunogenicity of MVA-based vaccine against tuberculosis.
    Kou Y; Xu Y; Zhao Z; Liu J; Wu Y; You Q; Wang L; Gao F; Cai L; Jiang C
    Immunol Lett; 2017 Oct; 190():51-57. PubMed ID: 28728855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of Homologous and Heterologous Prime-Boost Immunization Regimens of Recombinant Adenovirus and Modified Vaccinia Virus Ankara Expressing an Ag85B-TB10.4 Fusion Protein against
    Kou Y; Wan M; Shi W; Liu J; Zhao Z; Xu Y; Wei W; Sun B; Gao F; Cai L; Jiang C
    J Microbiol Biotechnol; 2018 Jun; 28(6):1022-1029. PubMed ID: 29847865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
    Kolibab K; Yang A; Derrick SC; Waldmann TA; Perera LP; Morris SL
    Clin Vaccine Immunol; 2010 May; 17(5):793-801. PubMed ID: 20357059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prime-boost vaccination with Bacillus Calmette Guerin and a recombinant adenovirus co-expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis induces robust antigen-specific immune responses in mice.
    Li W; Li M; Deng G; Zhao L; Liu X; Wang Y
    Mol Med Rep; 2015 Aug; 12(2):3073-80. PubMed ID: 25962477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous administration of modified vaccinia virus Ankara expressing an Ag85B-ESAT6 fusion protein, but not an adenovirus-based vaccine, protects mice against intravenous challenge with Mycobacterium tuberculosis.
    You Q; Jiang C; Wu Y; Yu X; Chen Y; Zhang X; Wei W; Wang Y; Tang Z; Jiang D; Wu Y; Wang C; Meng X; Zhao X; Kong W
    Scand J Immunol; 2012 Jan; 75(1):77-84. PubMed ID: 21916923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prime-boost bacillus Calmette-Guérin vaccination with lentivirus-vectored and DNA-based vaccines expressing antigens Ag85B and Rv3425 improves protective efficacy against Mycobacterium tuberculosis in mice.
    Xu Y; Yang E; Wang J; Li R; Li G; Liu G; Song N; Huang Q; Kong C; Wang H
    Immunology; 2014 Oct; 143(2):277-86. PubMed ID: 24773322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.
    Verreck FA; Vervenne RA; Kondova I; van Kralingen KW; Remarque EJ; Braskamp G; van der Werff NM; Kersbergen A; Ottenhoff TH; Heidt PJ; Gilbert SC; Gicquel B; Hill AV; Martin C; McShane H; Thomas AW
    PLoS One; 2009; 4(4):e5264. PubMed ID: 19367339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 Subtype C Mosaic Gag Expressed by BCG and MVA Elicits Persistent Effector T Cell Responses in a Prime-Boost Regimen in Mice.
    Jongwe TI; Chapman R; Douglass N; Chetty S; Chege G; Williamson AL
    PLoS One; 2016; 11(7):e0159141. PubMed ID: 27427967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant BCG coexpressing Ag85B, ESAT-6 and Rv3620c elicits specific Th1 immune responses in C57BL/6 mice.
    Yang E; Lu Y; Xu Y; Liang Q; Wang C; Wang H; Shen H
    Microb Pathog; 2014; 69-70():53-9. PubMed ID: 24726737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A recombinant adenovirus expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis elicits strong antigen-specific immune responses in mice.
    Li W; Deng G; Li M; Zeng J; Zhao L; Liu X; Wang Y
    Mol Immunol; 2014 Nov; 62(1):86-95. PubMed ID: 24980867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
    Goonetilleke NP; McShane H; Hannan CM; Anderson RJ; Brookes RH; Hill AV
    J Immunol; 2003 Aug; 171(3):1602-9. PubMed ID: 12874255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine expressing a fusion protein of Ag85B-Esat6-HspX in mice.
    Yuan W; Dong N; Zhang L; Liu J; Lin S; Xiang Z; Qiao H; Tong W; Qin C
    Vaccine; 2012 Mar; 30(14):2490-7. PubMed ID: 21704108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection.
    Yuan X; Teng X; Jing Y; Ma J; Tian M; Yu Q; Zhou L; Wang R; Wang W; Li L; Fan X
    Appl Microbiol Biotechnol; 2015 Dec; 99(24):10587-95. PubMed ID: 26363555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and protective efficacy of heterologous prime-boost regimens with mycobacterial vaccines and recombinant adenovirus- and poxvirus-vectored vaccines against murine tuberculosis.
    You Q; Wu Y; Wu Y; Wei W; Wang C; Jiang D; Yu X; Zhang X; Wang Y; Tang Z; Jiang C; Kong W
    Int J Infect Dis; 2012 Nov; 16(11):e816-25. PubMed ID: 22921259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and protective efficacy of mycobacterial DNA vaccines incorporating plasmid-encoded cytokines against Mycobacterium bovis.
    Young SL; Slobbe LJ; Peacey M; Gilbert SC; Buddle BM; de Lisle GW; Buchan GS
    Immunol Cell Biol; 2010 Aug; 88(6):651-7. PubMed ID: 20231853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection.
    Betts G; Poyntz H; Stylianou E; Reyes-Sandoval A; Cottingham M; Hill A; McShane H
    PLoS One; 2012; 7(12):e50447. PubMed ID: 23284637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with recombinant modified vaccinia virus Ankara prevents the onset of intestinal allergy in mice.
    Bohnen C; Wangorsch A; Schülke S; Nakajima-Adachi H; Hachimura S; Burggraf M; Süzer Y; Schwantes A; Sutter G; Waibler Z; Reese G; Toda M; Scheurer S; Vieths S
    Allergy; 2013 Aug; 68(8):1021-8. PubMed ID: 23909913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterologous Boost Following
    Wu Y; Cai M; Ma J; Teng X; Tian M; Bassuoney EBMB; Fan X
    Front Immunol; 2018; 9():2439. PubMed ID: 30425711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice.
    Li Q; Yu H; Zhang Y; Wang B; Jiang W; Da Z; Xian Q; Wang Y; Liu X; Zhu B
    Scand J Immunol; 2011 Jun; 73(6):568-76. PubMed ID: 21323695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis.
    Tchilian EZ; Desel C; Forbes EK; Bandermann S; Sander CR; Hill AV; McShane H; Kaufmann SH
    Infect Immun; 2009 Feb; 77(2):622-31. PubMed ID: 19064635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.